Getinge
This information is aimed exclusively at healthcare professionals or other professional audiences and is for informational purposes only, is not exhaustive and therefore should not be relied upon as a replacement of the Instructions for Use, service manual or medical advice. Getinge shall bear no responsibility or liability for any action or omission of any party based upon this material, and reliance is solely at the user’s risk.
Any therapy, solution or product mentioned might not be available or allowed in your country. Information may not be copied or used, in whole or in part, without written permission by Getinge. Views, opinions, and assertions expressed are strictly those of the interviewed and do not necessarily reflect or represent the views of Getinge.
THT 2023: Predictors for a Positive Hemodynamic & Clinical Response to Intra-aortic Counterpulsation
Welcome to the third presentation within the session, "THT 2023: MCS device selection in HF patients - Where does counterpulsation fit?", from the 2023 Technology and Heart Failure Therapeutics Conference.
The full-length session focuses on the unique physiological effects of counterpulsation in advanced heart failure patients. Moreover, the session provides guidance on MCS selection based on underlying etiology, clinical phenotyping, and predictors for positive hemodynamic and clinical response. Finally, you will be presented with novel applications for counterpulsation in HF.
To watch the full-length session, click here.
